Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism.
Liraglutide is a glucagon-like peptide-1 (GLP-1) mimetic used for the treatment of Type 2 diabetes. Similar to the actions of endogenous GLP-1, liraglutide potentiates the post-prandial release of insulin, inhibits glucagon release and increases satiety. Recent epidemiological studies and clinical t...
Збережено в:
| Автори: | , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Public Library of Science (PLoS)
2014-01-01
|
| Серія: | PLoS ONE |
| Онлайн доступ: | http://europepmc.org/articles/PMC4023984?pdf=render |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|